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WATER SOLUBLE AMINE ESTERS OF 
TESTOSTERONE FOR INTRANASAL 
ADMINISTRATION 
FIELD OF THE INVENTION 
This invention relates generally to novel Water-soluble 
prodrugs of testosterone suitable for intranasal administra 
tion to mammals, including humans, in need of testosterone 
replacement therapy. More speci?cally, this invention relates 
to a Water-soluble form of testosterone Which is suitable for 
intranasal administration. This invention also relates to a 
testosterone replacement therapy Which comprises intrana 
sal administration of one or more of the Water-soluble forms 
of testosterone of the present invention. 
BACKGROUND 
Testosterone (17B-hydroXyandrost-4-en-3-one) and its 
metabolite, dihydrotestosterone, are the primary endogenous 
androgenic hormones (androgens). Endogenous androgens 
are responsible for the normal groWth and development of 
the male seX organs and for development and maintenance 
of secondary seX characteristics. These effects include the 
groWth and maturation of the prostate, seminal vesicles, 
penis, and scrotum; the development of male hair 
distribution, such as facial, pubic, chest, and aXillary hair; 
laryngeal enlargement, vocal cord thickening, alterations in 
body musculature, and fat distribution. 
These compounds also cause retention of nitrogen, 
sodium, potassium phosphorous, and decreased urinary 
excretion of calcium. Androgens have also been reported to 
increase protein anabolism and decrease protein catabolism. 
Androgens are responsible for the groWth spurt of adoles 
cence and for the eventual termination of linear groWth 
brought about by fusion of the epiphyseal groWth centers. In 
children, eXogenous androgens accelerate linear groWth rate 
but may cause a disproportionate advancement in bone 
maturation. Androgens have been reported to stimulate the 
production of red blood cells by enhancing the production of 
erythropoietin. 
The range of plasma testosterone levels in normal adult 
men is from 10 to 35 nmol/L (3 to 10 ng/ml). There are 
clinical conditions in Which testosterone levels are decreased 
from normal levels. Disorders associated With hypotestoster 
onemia include primary hypogonadism (congenital or 
acquired), testicular failure due to cryptorchidism, bilateral 
torsion, Cushing’s syndrome, congenital adrenal 
hyperplasia, hyperprolactinemia, Kinefelter’s syndrome, 
orchitis, sickle cell anemia, Hodgkin’s disease, amyloidosis, 
cirrhosis of the liver, and chronic renal failure. Decreases in 
plasma testosterone may also accompany surgery, 
chemotherapy, spinal cord injury, myocardial infarction, 
severe burns, and toXic damage from eXposure to alcohol or 
heavy metals. In any or all of these conditions it may be 
desirable for the patient to undergo testosterone replacement 
therapy. 
Testosterone also antagoniZes a number of the effects of 
estrogens, and sometimes is employed clinically for this 
purpose. This is especially important in the suppression of 
metastatic carcinoma of the breasts. Testosterone and its 
esters (e.g., testosterone propionate) and derivatives (e.g., 
methyltestosterone) also promotes retention of calcium, and 
may be useful in treatment of osteoporosis. 
HoWever, oral administration of testosterone itself is 
generally ineffective as a means for increasing circulating 
testosterone levels. When testosterone per se is administered 
by mouth, it is absorbed into the portal blood and degraded 
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promptly by the liver so that insigni?cant amounts reach the 
systemic circulation; When injected parenterally, testoster 
one is rapidly absorbed from the injection vehicle and 
rapidly degraded. As a consequence, effective androgen 
therapy requires either the administration of testosterone in 
a sloWly absorbed dosage form or the administration of 
modi?ed analogs of testosterone dissolved in oil vehicle. 
Such chemical modi?cations represent attempts to retard the 
rate of metabolism of testosterone, so as to sustain effective 
blood levels, due to sloW conversion of the ester. Three types 
of modi?cation of the molecule have received Widespread 
clinical application, namely, esteri?cation of the 176 
hydroXyl group, alkylation at the 17a position, and modi 
?cation of the ring structure, particularly substitutions at the 
2, 9, and 11 positions. Most agents actually contain combi 
nations of ring structure alterations and either 170. 
alkylation or esteri?cation of the 17[3-hydroXyl moiety. 
Esteri?cation serves to decrease the polarity of the molecule. 
Consequently, the steroid is more soluble in the fat vehicles 
used for injection, and release of the steroid into the circu 
lation is sloWed. Most esters must be injected parenterally, 
a route of administration Which, because it is painful and 
inconvenient, is dif?cult for patients to self-administer in a 
chronic therapeutic regimen. Furthermore, the more carbon 
molecules in the acid esteri?ed, the more prolonged is the 
action of the modi?ed compound. Esters such as testoster 
one cypionate (testosterone cyclopentanepropionate) and 
testosterone enanthate (testosterone heptanoate) are typi 
cally injected every 1 to 3 Weeks. These esters are hydro 
lyZed before the hormones act; thus the effectiveness of 
therapy must be monitored by assaying plasma testosterone 
level With time folloWing administration. 
The oral effectiveness of 17ot-alkylated androgens (such 
as methyl-testosterone and methandrostenolone) is due to 
sloWer hepatic catabolism than occurs With testosterone 
itself, so that the alkylated derivatives escape degradation by 
the liver and reach the systemic circulation. For this reason, 
17ot-methyl or -ethyl substitution is a common feature of 
most orally active androgens. Unfortunately, all 170. 
alkylated steroids can produce cholestatic hepatitis and 
jaundice, and other liver function abnormalities such as 
elevation of plasma alkaline phosphatase and conjugated 
bilirubin, even at loW doses. The most serious complications 
of 17ot-alkylated androgen therapy are the development of 
peliosis hepatitis (blood-?lled cysts in the liver) and 
hepatoma. While patients With preexisting liver disease are 
particularly susceptible to these serious side effects, they are 
frequently seen even in patients Without a history of clinical 
liver disease. 17ot-Alkylated drugs also cause an increase in 
a variety of plasma proteins that are synthesiZed in the liver. 
Finally, the relatively infrequent administration of these 
drugs results in a Wide range in postadministration plasma 
testosterone values. 
Although testosterone is knoWn to be absorbed from the 
nasal cavity, its insolubility in Water makes its intranasal 
administration impractical (see, e.g., Hussain et al., J. 
Pharm. Sci. 73: 1300—1301, 1984). Transdermal prepara 
tions of testosterone in Which a testosterone-loaded patch is 
applied each day have recently become available 
(Testoderm®, AlZa Corporation, Palo Alto, Calif.). This 
therapy avoids the Wide sWings in serum testosterone values 
that occur betWeen injections of testosterone esters, and 
alloWs for self-administration by the patient. HoWever, the 
transdermal patch Will not produce adequate serum testoster 
one concentration if applied to nongenital skin. In order to 
deliver an effective amount of testosterone into the 
bloodstream, the transdermal patch must be applied directly 
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to a shaved area of the scrotum, Where it must be Worn for 
22—24 hours per day. Furthermore, any testosterone remain 
ing on the skin following removal of the patch may be 
transferred to the patient’s sexual partner. Finally, the trans 
dermal patch suffers from the disadvantage of being 
extremely expensive. 
In vieW of the foregoing, it is apparent that there exists a 
need in the art for an improved method of delivery of 
testosterone for use in testosterone replacement therapy. 
Surprisingly, the present inventor has found that intrana 
sal administration of a novel form of testosterone offers 
signi?cant advantages over the prior art. Those advantages 
include rapid absorption, and easy and reliable self 
administration. 
SUMMARY OF THE INVENTION 
Accordingly, since parenteral administration of testoster 
one analogs results in Wide sWings in plasma testosterone 
levels, and since chronic self-administration of injectable 
dosage forms is impractical, and since transdermal dosage 
forms are expensive and inconvenient, it is an object of the 
present invention to provide a Water-soluble form of test 
osterone suitable for intranasal administration for use in 
testosterone replacement therapy. 
It is a further aspect of this invention to provide a 
Water-soluble form of testosterone suitable for intranasal 
administration Which is equal to or superior to prior art 
injectable and transdermal dosage forms in many respects, 
including effectiveness, but Which avoids many of the prob 
lems associated With injectable and transdermal dosage 
forms, While offering superior ease of administration. 
It is yet a further aspect of this invention to provide a 
method of testosterone replacement therapy by intranasally 
administering the Water-soluble form of testosterone of the 
present invention to a mammalian organism, especially a 
human, in need of testosterone replacement therapy. 
It is a still further aspect of this invention to provide a 
method for administering testosterone Which is equal to or 
superior to administration of injectable dosage forms in 
many respects, including effectiveness, but Which avoids 
many of the problems associated With injectable dosage 
forms, While offering superior ease of administration. 
A further aspect of this invention is to provide a pharma 
ceutical composition suitable for intranasal administration, 
for use in testosterone replacement therapy. Accordingly, the 
composition of the present invention comprises an effective 
amount of the Water-soluble form of testosterone of the 
present invention achieve a desired testosterone level, and a 
pharmaceutically acceptable carrier therefor. 
With the foregoing and other objects, advantages and 
features of the invention that Will become hereinafter 
apparent, the nature of the invention may be more clearly 
understood by reference to the folloWing detailed descrip 
tion of the preferred embodiments of the invention and to the 
appended claims. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1: Time course of plasma levels of testosteronyl, 
N,N-dimethyl amine glyconate (TSDG) and testosterone 
(TS) folloWing intranasal administration of TSDG (25.0 
mg.kg) in rats. 
FIG. 2: Time course of conversion of TSDG to TS in liver 
homogenate. 
FIG. 3: Time course plot illustrating stability of TSDG in 
H20. 
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DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENTS OF THE 
INVENTION 
The present invention is a neW Water-soluble testosterone 
prodrug suitable for intranasal administration. The intranasal 
administration of testosterone prodrugs offers signi?cant 
clinical advantages over the prior art. Furthermore, the 
present invention provides a safe, effective and convenient 
treatment for testosterone de?ciency by intranasally admin 
istering the Water-soluble testosterone prodrugs of the 
present invention. This avoids the problems associated With 
the injectable and transdermal dosage forms of testosterone. 
The present inventor has found that intranasal adminis 
tration of the Water-soluble testosterone prodrugs of the 
present invention may be advantageously used in a regimen 
of testosterone replacement therapy. Intranasal administra 
tion of these compounds is as effective as intravenous 
administration, hoWever, intranasal administration offers the 
signi?cant advantage that it can be conveniently and pain 
lessly self-administered by the patient. 
Preferred testosterone prodrugs Will have the folloWing 
chemical structure: 
OR 
CH3 
0 
Wherein R has the folloWing chemical structure: 
and R1 and R2 are loWer alkyl, more preferably straight 
chain alkyl, most preferably methyl, ethyl, or propyl. The 
most preferred Water-soluble testosterone prodrug is 
testosteronyl, N,N-dimethyl amine glyconate (TSDG). Phar 
maceutically acceptable salts of the compounds of the 
present invention are also preferred. 
Pharmaceutically acceptable salts include, but are not 
limited to, salts of organic carboxylic acids, such as acetic, 
lactic, tartaric, malic, isothionic, lactobionic and succinic 
acids; organic sulfonic acids, such as methanesulfonic, 
ethanesulfonic, benZenesulfonic and p-tolylsulfonic acids, 
and inorganic acids, such as hydrochloric, sulfuric, phos 
phoric and sulfamic acids. 
A further aspect of this invention is a pharmaceutical 
composition of matter for intranasal testosterone replace 
ment therapy that comprises the Water-soluble testosterone 
prodrugs as described above, mixtures of Water-soluble 
testosterone prodrugs, and/or pharmaceutical salts thereof, 
and pharmaceutically acceptable carriers therefor. Such 
compositions are prepared in accordance With accepted 
pharmaceutical procedures, for example, as described in 
Remington ’s Pharmaceutical Sciences, seventeenth edition, 
ed. Alfonso R. Gennaro, Mack Publishing Company, Easton, 
Pa., Eighteenth edition (1990). 
For therapeutic use in a regimen of testosterone replace 
ment therapy, a Water-soluble testosterone prodrug, or its 
salt, can be conveniently administered in the form of a nasal 
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pharmaceutical composition containing a Water-soluble tes 
tosterone prodrug, or its salt, and a pharmaceutically accept 
able carrier therefor. Suitable carriers for intranasal admin 
istration are Well knoWn to those skilled in the art and vary 
With the desired form and mode of administration of the 
pharmaceutical composition. Typically, the carrier may be a 
liquid, suspension, semi-solid, gel, or vaporiZable carrier, or 
combinations thereof. In a preferred embodiment, the carrier 
is a pharmaceutically acceptable aqueous carrier. 
The compound of the present invention or its salt may be 
formulated together With the carrier into any desired unit 
dosage form. Unit dosage forms such as solutions, 
suspensions, and Water-miscible semisolids are particularly 
preferred. 
Each carrier must be “acceptable” in the sense of being 
compatible With the other ingredients in the formulation and 
not injurious to the patient. The carrier must be biologically 
acceptable and inert. To prepare formulations suitable for 
intranasal administration, solutions and suspensions are ster 
iliZed and are preferably isotonic to blood. 
The formulations may conveniently be presented in unit 
dosage form and may be prepared by any method knoWn in 
the art. Such methods include the step of bringing the active 
ingredient into association With the carrier Which itself may 
encompass one or more accessory ingredients. In general, 
the formulations are prepared by uniformly and intimately 
bringing into association the active ingredient With liquid 
carriers or ?nely divided semi-solid carriers or both. Various 
unit dose and multidose containers, e.g., sealed ampules and 
vials, may be used, as is Well knoWn in the art. 
In addition to the ingredients particularly mentioned 
above, the formulations of this invention may also include 
other agents conventional in the art for this type of intranasal 
pharmaceutical formulation. 
The present invention is also directed to a method of 
increasing plasma levels of testosterone in a mammal, e.g., 
a human, by treating the mammal With an effective amount 
of a Water-soluble testosterone prodrug. For purposes of the 
present invention, the patient can be any mammal in need of 
increased plasma levels of testosterone. 
The dosage of the Water-soluble testosterone prodrug or 
mixture thereof administered to a patient Will vary depend 
ing on several factors, including, but not limited to, the age, 
Weight, and species of the patient, the general health of the 
patient, the severity of the symptoms, the potency of the 
Water-soluble testosterone prodrug, Whether the composition 
is being administered alone or in combination With other 
agents, the incidence of side effects and the like. 
For instance, the desired dose may be administered as 1 
to 6 or more subdoses administered at appropriate intervals 
throughout the day. The compounds may be administered 
repeatedly over a period of months or years, or it may be 
sloWly and constantly administered to the patient. Higher 
and loWer doses may also be administered. 
The daily dose may be adjusted taking into account, for 
example, the above-identi?ed variety of parameters. 
Typically, the present compositions may be administered 
intranasally in an amount of about 0.001 to 100.0 mg/kg 
body Weight/day. HoWever, other amounts may also be 
administered. 
To achieve good plasma concentrations, the active com 
pounds may be administered, for instance, by intranasal 
administration of an approximate 0.1 to 1M solution of the 
active ingredient, optionally in saline. 
While it is possible for the active ingredient to be admin 
istered alone, it is preferably administered in a pharmaceu 
tical formulation. The formulations of the present invention 
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comprise at least one active ingredient, as de?ned above, 
together With one or more acceptable carriers thereof and 
optionally other therapeutic agents. 
The above method may be practiced by administration of 
the compounds by themselves or in a combination With other 
active ingredients in a pharmaceutical composition. Other 
therapeutic agents suitable for use herein are any compatible 
drugs that are effective by the same or other mechanisms for 
the intended purpose, or drugs that are complementary to 
those of the claimed invention. 
The compounds utiliZed in combination therapy may be 
administered simultaneously, in either separate or combined 
formulations, or at different times than the present 
compounds, e.g., sequentially, such that a combined effect is 
achieved. The amounts and regime of administration Will be 
adjusted by the practitioner, by preferably initially loWering 
their standard doses and then titrating the results obtained. 
The method of the present invention may be used in con 
junction With other therapies as determined by the practi 
tioner. 
The present invention may be used to increase plasma 
testosterone levels in patients suffering from, for instance, 
primary hypogonadism (congenital or acquired), testicular 
failure due to cryptorchidism, bilateral torsion, Cushing’s 
syndrome, congenital adrenal hyperplasia, 
hyperprolactinemia, Klinefelter’s syndrome, orchitis, sickle 
cell anemia, Hodgkin’s disease, amyloidosis, cirrhosis of the 
liver, and chronic renal failure. Decreases in plasma test 
osterone may also accompany surgery, chemotherapy, spinal 
cord injury, myocardial infarction, severe burns, and toxic 
damage from exposure to alcohol or heavy metals. HoWever, 
the preceding conditions are not intended to be limiting, and 
treatment of any condition Which requires increased plasma 
testosterone levels is intended to be encompassed by the 
present invention. 
Having noW generally described this invention, the same 
Will be better understood by reference to certain speci?c 
examples, Which are included herein for purposes of illus 
tration only and are not intended to be limiting of the 
invention or any embodiment thereof, unless so speci?ed. 
EXAMPLE 
Intranasal Administration of TSDG 
The nasal absorption of the Water soluble testosterone 
prodrug TSDG Was studied using an in vivo experimental 
technique previously described by Huang et al. 
(J.Pharmaceut. Sci, 74: 608—611, 1985). 
Male Sprague-DaWley rats Weighing 250—275 gm Were 
used. Animals Were fasted overnight before the experiment, 
but Water Was given ad libitum. All surgical procedures Were 
performed under sodium pentobarbital anesthesia (40 mg/kg 
i.p.). An incision Was made in the neck, and the trachea Was 
cannulated With a polyethylene tube. A closed tube Was 
inserted through the esophagus to the posterior part of the 
nasal cavity. The nasopalatine passage Was closed With an 
adhesive agent to prevent drainage of the drug from the nasal 
cavity to the mouth. 
Blood samples Were collected from a cannula inserted 
into the femoral artery. For intravenous administration, the 
jugular vein Was cannulated for administering the dose. 
Preparation of the Solutions 
Drug solutions at 25 and 50 mg/kg/0.2 ml equimolar 
doses of TSDG Were freshly prepared by using 0.05M 
phosphate buffer at pH 6.0. For nasal administration, aque 
ous solutions of TSDG and testosterone Were administered 
through the nostril using a microsyringe. For intravenous 
administration, the same dose of the drug Was injected 
through the jugular vein. 
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Sample Collection after Nasal and Intravenous Administra 
tions 
Blood samples Were collected at 0, 5, 10, 20, 30, 40, 60, 
90, 120, 150, and 180 minutes. After immediate centrifuga 
tion (3000><g for 3 min), the plasma Was separated. The 
animal Was sacri?ced after the last sample Was obtained, and 
the samples Were then analyZed by HPLC, using the method 
of Hsyu et al. (Pharm. Res. 11:156—159, 1994). Brie?y, 
plasma concentrations of testosterone free base Were deter 
mined via a HPLC protocol Which included solid-phase 
extraction, separation on a reverse-phase cyano column, and 
UV detection at 305 nm. 
Results 
Table 1 shoWs area under the curve (AUC; pg’khr/ml) after 
intravenous and intranasal administration of TSDG and 
testosterone (TS) at doses of 50 mg/kg and 25 mg/kg. 
TABLE 1 
DOSE 50 mg/kg 25 mg/kg 
ROUTE Intravenous Intranasal Intravenous Intranasal 
AUC for TSDG 2.83 2.66 1.65 1.63 
AUC for TS 3.78 3.49 1.77 1.83 
The ?gure shoWs plasma TSDG and TS levels after 
intranasal administration at a dose of 25.0 mg/kg. Absorp 
tion of TSDG Was rapid; plasma levels at all time points 
Were comparable to those following intravenous adminis 
tration. 
TSDG Was also found to convert rapidly to TS in human 
liver homogenate as shoWn in FIG. 2. On the other hand, 
TSDG Was found to be very stable in Water, as shoWn in 
FIG. 3. 
While the invention has been described herein by refer 
ences to various speci?c materials, procedures, and 
examples, it is understood that the invention is not restricted 
to the particular materials, combinations of materials, and 
procedures selected for that purpose. Numerous variations 
of such details can be implied and Will be appreciated by 
those skilled in the art. 
What is claimed is: 
1. AWater-soluble testosterone analog having the folloW 
ing chemical structure: 
OR 
CH3 
CH3 
0 
Wherein R is: 
R1 / 
—C—CH2—N 
0 R2 
and R1 and R2 are loWer alkyl. 
2. Atestosterone analog according to claim 1, Wherein R1 
and R2 are straight-chain alkyl. 
3. Atestosterone analog according to claim 1, Wherein R1 
and R2 are methyl, ethyl, or propyl. 
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4. An intranasal pharmaceutical composition comprising 
a testosterone analog having the folloWing chemical struc 
ture: 
5 OR 
CH3 
CH3 
10 
wherein R is: 
15 
0 R2 
20 
and Wherein R1 and R2 are loWer alkyl, and a pharmaceu 
tically acceptable carrier therefor. 
5. A pharmaceutical composition comprising a testoster 
one analog according to claim 2 and a pharmaceutically 
acceptable carrier therefor. 
6. A pharmaceutical composition comprising a testoster 
one analog according to claim 3 and a pharmaceutically 
acceptable carrier therefor. 
7. A method for increasing plasma testosterone levels 
comprising intranasally administering to a mammal in need 
of such treatment an effective amount of a testosterone 
analog having the folloWing structure: 
30 
OR 
35 CH3 
CH3 
40 
wherein R is: 
45 
R1 
50 
and Wherein R1 and R2 are loWer alkyl. 
8. The method of claim 7, Wherein the testosterone analog 
is administered at a dose of 0.1 to 1.0 mg/kg body Weight/ 
day. 
9. A method for increasing plasma testosterone levels 
comprising intranasally administering to a patient in need of 
such treatment an effective amount of a testosterone analog 
according to claim 2. 
10. The method of claim 9, Wherein the testosterone 
analog is administered at a dose of 0.1 to 1.0 mg/kg body 
Weight/day. 
11. A method for increasing plasma testosterone levels 
comprising intranasally administering to a patient in need of 
such treatment an effective amount of a testosterone analog 
according to claim 3. 
12. The method of claim 11, Wherein the testosterone 
analog is administered at a dose of 0.1 to 1.0 mg/kg body 
Weight/day. 
55 
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13. A method for increasing plasma testosterone levels 
comprising intranasally administering to a patient in need of 
such treatment an effective amount of the pharmaceutical 
composition of claim 4. 
14. A method for increasing plasma testosterone levels 
comprising intranasally administering to a patient in need of 
such treatment an effective amount of the pharmaceutical 
composition of claim 5. 
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15. A method for increasing plasma testosterone levels 
comprising intranasally administering to a patient in need of 
such treatment an effective amount of the pharmaceutical 
composition of claim 6. 
